Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cronos Australia Ltd. ( (AU:VIT) ).
Vitura Health Limited reported its FY2025 financial results, highlighting a modest revenue increase to $124.04 million and a significant 23.5% rise in EBITDA to $7.63 million. Despite facing industry-wide price declines in medicinal cannabis, Vitura’s strategic acquisitions and operational efficiencies contributed to its growth. The company expanded its patient base through acquisitions such as Candor Medical and Releaf Group, and saw substantial growth in its telehealth business, Doctors on Demand. However, net profit after tax decreased by 5.8% due to higher amortization and interest costs. Vitura’s strategic repositioning and focus on cost management underscore its resilience in a competitive market.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
More about Cronos Australia Ltd.
Vitura Health Limited is a leading digital health company, primarily involved in the sale and distribution of medicinal cannabis and digital medical consultation services. The company focuses on expanding its market reach through strategic acquisitions and leveraging technology to enhance patient-prescription-medication connectivity.
Average Trading Volume: 243,037
Technical Sentiment Signal: Sell
Current Market Cap: A$45.03M
Learn more about VIT stock on TipRanks’ Stock Analysis page.